Calidi Biotherapeutics In... (CLDI)
0.77
-0.03 (-3.27%)
At close: Mar 13, 2025, 11:23 AM
-3.27% (1D)
| Bid | 0.77 |
| Market Cap | 19.95M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -71.53M |
| EPS (ttm) | -1.04 |
| PE Ratio (ttm) | -0.74 |
| Forward PE | -0.73 |
| Analyst | Buy |
| Ask | 0.78 |
| Volume | 92,975 |
| Avg. Volume (20D) | 1,592,250 |
| Open | 0.82 |
| Previous Close | 0.80 |
| Day's Range | 0.76 - 0.82 |
| 52-Week Range | 0.58 - 8.30 |
| Beta | 1.05 |
About CLDI
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enha...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 1, 2021
Employees 41
Stock Exchange AMEX
Ticker Symbol CLDI
Website https://calidibio.com
Analyst Forecast
According to 3 analyst ratings, the average rating for CLDI stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 2497.40% from the latest price.
Stock Forecasts2 months ago
-32.22%
Calidi Biotherapeutics shares are trading lower af...
Unlock content with
Pro Subscription
2 months ago
-8.16%
Calidi Biotherapeutics shares are trading lower after the company announced a public offering.
